Galera Therapeutics, Inc. (GRTX)

Galera Therapeutics, Inc. (GRTX) — VMCI valuation read

Across 120 indicators, Galera Therapeutics, Inc. (GRTX) lands at VMCI 57/100. The Healthcare sector median is 50, so the 7-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on GRTX in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, GRTX trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 0.3x leaves covenant headroom for GRTX on the trailing balance sheet.

GRTX rose 2.8% over the trailing 7 days, with a -16.1% read on a 30-day basis.